ArticleAmerican journal of translational research2025
NRF2-mediated autophagic degradation of glycated vimentin in the skin by an elastin-derived peptide.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdvanced glycation end products (AGEs) contribute significantly to skin ageing by inducing cross-linking of dermal proteins and promoting oxidative stress. Vimentin, a long-lived intermediate filament protein, is particularly susceptible to glycation and serves as a biomarker for skin ageing and fibrosis. NRF2 (nuclear factor erythroid 2-related factor 2) is a key regulator of cellular defense mechanisms, including antioxidant responses and autophagy.
methodsWe evaluated the anti-glycation and pro-regenerative properties of a trifunctional elastin-derived peptide (TFP) in human dermal fibroblasts (
resultsTFP reduced vimentin glycation across all models. In skin explants, total vimentin levels decreased without changes in
conclusionTFP activates NRF2-mediated detoxification and protein clearance pathways, facilitating the removal of glycated vimentin. These results highlight TFP's anti-ageing, anti-fibrotic, and anti-inflammatory potential, positioning it as a promising therapeutic candidate for ageing-related skin conditions and disorders associated with proteostasis imbalance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.